NCT07241676Enrolling by invitation
Early Recurrence After Surgery for Pancreatic Cancer
Early Recurrence and Futility After Curative-intent Resection of Pancreatic Ductal Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
The goal of this observational study is to learn about early recurrence after curative-intent surgery for pancreatic cancer. The main questions it aims to answer are: * How often does early recurrence (within 12 months after surgery) occur? * When does it happen, and at which anatomical sites (liver, lung, local, peritoneum)? * How is recurrence detected (imaging or tumor markers)? Adults with histologically confirmed pancreatic ductal adenocarcinoma who undergo curative-intent resection without distant metastases will be enrolled. Participants will be followed according to routine clinical care at each hospital, typically with imaging and CA19-9 blood tests. No study-specific interventions are required.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 23 Oct 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Azienda Ospedaliera di Padova
- Diseases
- Pancreatic cancer
- NCT number
- NCT07241676
What you commit to
- Study type: Observational
- Planned participants: 500
- From 23 Oct 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgery performed for palliative or diagnostic purposes only
Other illness
- Intraoperative discovery of unresectable disease or distant metastases
- Gross residual disease (R2 resection)
Other
- Withdrawal of informed consent
- Pathological diagnosis other than PDAC (e.g., neuroendocrine tumor, acinar cell carcinoma, invasive IPMN)
- Incomplete clinical or radiologic follow-up precluding recurrence assessment
- Absence of adequate preoperative contrast-enhanced pancreas-protocol CT or MRI preventing accurate staging and metastatic evaluation
- Interval \>9 months between two consecutive follow-up visits
- Major protocol deviations or insufficient data, as judged by the site investigator
Who the study is looking for
- Age ≥18 years
- Histologically confirmed pancreatic ductal adenocarcinoma (PDAC)
- Undergoing curative-intent resection (R0 or R1)
- No evidence of distant metastasis at the time of surgery
- Availability of preoperative CA19-9 value and pancreas-protocol CT or MRI
- Ability to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Padova Coordinator of this site? Confirm its status | Padova | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.